肺がん診断およびスクリーニングの世界市場レポート 2024

肺がん診断およびスクリーニングの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.2%の年間複合成長率（CAGR）で33億米ドルに成長すると予想されています。予測期間に予想される成長は、肺がんの発生率の増加、早期発見の重視の高まり、ハイリスク検査プログラムの拡大、個別化医療への移行、政府の取り組みと資金提供など、いくつかの要因によって推進されています。予測期間中に予想される主な動向には、新しいスクリーニング手段の出現、バイオマーカー検査の進歩、人工知能（AI）の統合、リキッドバイオプシー技術の採用増加、早期発見への重点、および低線量CTスクリーニングプログラムの拡大が含まれます。

肺がんの罹患率の予測増加は、予見可能な将来において肺がん診断およびスクリーニング市場の成長を促進する態勢が整っています。肺がんは、咳、胸痛、呼吸困難などの症状を特徴とし、肺組織内の異常細胞の制御されない増殖を特徴とする悪性疾患です。肺がん診断およびスクリーニング方法は、切開生検や気管支鏡検査などのさまざまな検査を利用して、早期発見に重要な役割を果たします。 2023年 1月の時点で、米国がん協会のデータによると、米国では約238,340人の新規肺がん患者が発生し、127,070人の死亡が報告されています。この肺がん症例の急増は、診断およびスクリーニング対策の重要性を強調し、それによって肺がん診断およびスクリーニング市場の成長を促進します。

ヘルスケア費の増加傾向により、肺がん診断およびスクリーニング市場の拡大がさらに促進されると予想されます。ヘルスケア支出には、医療サービス、治療、医療関連の物品や活動の提供と受信に関連する総費用が含まれます。 肺がん診断およびスクリーニングメソッドの実装は、早期発見を促進し、長期的な治療費を削減し、患者の転帰を向上させる可能性があるため、ヘルスケア費の削減に貢献します。 2022年 11月、カナダ保健情報研究所（CIHI）は、カナダの総医療支出が0.8%増加し、2021年の3,280億米ドルから2022年には3,310億米ドルに達すると予測しました。このヘルスケア支出の上昇傾向は、カナダの肺がん診断およびスクリーニング市場成長の主要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の肺がん診断およびスクリーニング市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 機器
• 消耗品と付属品
• 世界の肺がん診断およびスクリーニング市場、検査別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• バイオマーカー検査
• 画像検査
• 生検
• 血液検査
• その他の検査
• 世界の肺がん診断およびスクリーニング市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 非小細胞肺がん
• 小細胞肺がん
• 世界の肺がん診断およびスクリーニング市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 独立診断ラボ
• 画像診断センター
• がん研究
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の肺がん診断およびスクリーニング市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の肺がん診断およびスクリーニング市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺がん診断およびスクリーニング市場の競合情勢
• 肺がん診断およびスクリーニング市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • AstraZeneca Plc

第31章 その他の大手および革新的な企業

• Abbott Laboratories Inc.
• Medtronic Plc.
• Danaher Corporation
• Siemens Healthcare GmbH
• FUJIFILM Corporation
• Koninklijke Philips NV
• GE Healthcare Bio Sciences AB
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Illumina Inc.
• Qiagen Inc.
• Myriad Genetic Laboratories Inc.
• NeoGenomics Laboratories Inc.
• Canon Medical Systems Corporation
• Eon Health Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Lung cancer diagnosis and screening involve employing examinations and techniques to detect and identify lung cancer, aiming for early detection and accurate diagnosis to facilitate effective treatment planning. This process is commonly applied in the treatment of squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

The primary products associated with lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are products utilized to analyze the results of diagnostic tests and process samples for diagnostic purposes. Various tests, such as biomarker tests, imaging tests, biopsy, and blood tests, are employed for different cancer types, including non-small cell lung cancer and small cell lung cancer. These diagnostic tools find application across diverse end-users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer diagnostic and screening market size has grown rapidly in recent years. It will grow from $2.11 billion in 2023 to $2.32 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The expansion observed in the historical period can be credited to several factors, including the growth of digital imaging, the standardization of screening protocols, public health initiatives aimed at reducing tobacco use, the establishment of cancer registries, and advancements in pathology analysis.

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.3 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period is driven by several factors, including the increasing incidence of lung cancer, a growing emphasis on early detection, the expansion of high-risk screening programs, a shift towards personalized medicine, and government initiatives and funding. Key trends expected in the forecast period encompass the emergence of novel screening modalities, advancements in biomarker testing, the integration of artificial intelligence (AI), an increase in the adoption of liquid biopsy techniques, a focus on early stage detection, and the expansion of low-dose CT screening programs.

The projected increase in the prevalence of lung cancer is poised to drive the growth of the lung cancer diagnostic and screening market in the foreseeable future. Lung cancer, characterized by symptoms such as coughing, chest pain, and difficulty breathing, is a malignant disease marked by the uncontrolled proliferation of abnormal cells in lung tissues. Diagnostic and screening methods for lung cancer play a crucial role in early detection, utilizing various tests such as incisional biopsy and bronchoscopy. As of January 2023, data from the American Cancer Society indicates approximately 238,340 new cases of lung cancer in the United States, with 127,070 reported deaths. This surge in lung cancer cases underscores the significance of diagnostic and screening measures, thereby fueling the growth of the lung cancer diagnostic and screening market.

The upward trajectory of healthcare expenditures is anticipated to further propel the expansion of the lung cancer diagnostic and screening market. Healthcare expenditures encompass the total costs associated with providing and receiving medical services, treatments, and healthcare-related goods and activities. The implementation of lung cancer diagnostic and screening methods contributes to healthcare expenditures by facilitating early detection, potentially reducing long-term treatment costs, and enhancing patient outcomes. In November 2022, the Canadian Institute for Health Information (CIHI) projected a 0.8% increase in total health spending in Canada, reaching $331 billion in 2022 from $328 billion in 2021. This upward trend in healthcare expenditures is a key driver in the growth of the lung cancer diagnostic and screening market.

Technological innovations stand out as a prominent trend gaining traction in the lung cancer diagnostics and screening market. Leading companies within this sector are actively introducing cutting-edge technologies to maintain their competitive positions. A notable example is Auris Health, a US-based robotic medical company, which, in December 2021, unveiled the MONARCH Robotic-Assisted Bronchoscopy procedure. This groundbreaking procedure allows physicians to accurately diagnose small and hard-to-reach lung nodules, facilitating biopsies for the early diagnosis and treatment of lung diseases.

Major players in the lung cancer diagnostics and screening market are strategically focused on the development of blood-based tests that leverage machine learning, specifically whole-genome machine learning. This approach involves applying machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, exemplified this strategy in October 2023 with the launch of FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with an impressive 99.7% negative predictive value (NPV). Designed for routine blood work, the test identifies individuals with potential lung cancer, including those in early stages, aiming to improve population health by addressing low uptake of low-dose computed tomography (LDCT) screening.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. This acquisition is anticipated to strengthen RadNet Inc.'s leadership in developing and deploying artificial intelligence (AI) for improved patient care and health. It also accelerates their growth and innovation pipeline, providing automated and integrated AI oncology solutions for clinicians. Aidence BV, based in the Netherlands, is a healthcare technology company with a focus on clinical solutions for lung cancer screening and pulmonary nodule treatment.

Major companies operating in the lung cancer diagnostic and screening market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories Inc., Medtronic Plc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Eon Health Inc., Oncimmune Holdings PLC, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, iDNA

North America was the largest region in the lung cancer diagnostic and screening market in 2023. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Diagnostic And Screening Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer diagnostic and screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer diagnostic and screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product: Instruments; Consumables And Accessories
• 2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests
• 3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
• 4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Diagnostic And Screening Market Characteristics

3. Lung Cancer Diagnostic And Screening Market Trends And Strategies

4. Lung Cancer Diagnostic And Screening Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Lung Cancer Diagnostic And Screening Market Size and Growth

• 5.1. Global Lung Cancer Diagnostic And Screening Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Lung Cancer Diagnostic And Screening Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Lung Cancer Diagnostic And Screening Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Lung Cancer Diagnostic And Screening Market Segmentation

• 6.1. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Instruments
• Consumables And Accessories
• 6.2. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Biomarkers Tests
• Imaging Test
• Biopsy
• Blood Test
• Other Tests
• 6.3. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• 6.4. Global Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Other End-Users

7. Lung Cancer Diagnostic And Screening Market Regional And Country Analysis

• 7.1. Global Lung Cancer Diagnostic And Screening Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Lung Cancer Diagnostic And Screening Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Lung Cancer Diagnostic And Screening Market

• 8.1. Asia-Pacific Lung Cancer Diagnostic And Screening Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Lung Cancer Diagnostic And Screening Market

• 9.1. China Lung Cancer Diagnostic And Screening Market Overview
• 9.2. China Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Lung Cancer Diagnostic And Screening Market

• 10.1. India Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Lung Cancer Diagnostic And Screening Market

• 11.1. Japan Lung Cancer Diagnostic And Screening Market Overview
• 11.2. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Lung Cancer Diagnostic And Screening Market

• 12.1. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Lung Cancer Diagnostic And Screening Market

• 13.1. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Lung Cancer Diagnostic And Screening Market

• 14.1. South Korea Lung Cancer Diagnostic And Screening Market Overview
• 14.2. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Lung Cancer Diagnostic And Screening Market

• 15.1. Western Europe Lung Cancer Diagnostic And Screening Market Overview
• 15.2. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Lung Cancer Diagnostic And Screening Market

• 16.1. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Lung Cancer Diagnostic And Screening Market

• 17.1. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Lung Cancer Diagnostic And Screening Market

• 18.1. France Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Lung Cancer Diagnostic And Screening Market

• 19.1. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Lung Cancer Diagnostic And Screening Market

• 20.1. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Lung Cancer Diagnostic And Screening Market

• 21.1. Eastern Europe Lung Cancer Diagnostic And Screening Market Overview
• 21.2. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Lung Cancer Diagnostic And Screening Market

• 22.1. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Lung Cancer Diagnostic And Screening Market

• 23.1. North America Lung Cancer Diagnostic And Screening Market Overview
• 23.2. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Lung Cancer Diagnostic And Screening Market

• 24.1. USA Lung Cancer Diagnostic And Screening Market Overview
• 24.2. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Lung Cancer Diagnostic And Screening Market

• 25.1. Canada Lung Cancer Diagnostic And Screening Market Overview
• 25.2. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Lung Cancer Diagnostic And Screening Market

• 26.1. South America Lung Cancer Diagnostic And Screening Market Overview
• 26.2. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Lung Cancer Diagnostic And Screening Market

• 27.1. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Lung Cancer Diagnostic And Screening Market

• 28.1. Middle East Lung Cancer Diagnostic And Screening Market Overview
• 28.2. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Lung Cancer Diagnostic And Screening Market

• 29.1. Africa Lung Cancer Diagnostic And Screening Market Overview
• 29.2. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Lung Cancer Diagnostic And Screening Market Competitive Landscape And Company Profiles

• 30.1. Lung Cancer Diagnostic And Screening Market Competitive Landscape
• 30.2. Lung Cancer Diagnostic And Screening Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bristol-Myers Squibb Company
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Thermo Fisher Scientific Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AstraZeneca Plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Lung Cancer Diagnostic And Screening Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories Inc.
• 31.2. Medtronic Plc.
• 31.3. Danaher Corporation
• 31.4. Siemens Healthcare GmbH
• 31.5. FUJIFILM Corporation
• 31.6. Koninklijke Philips N.V.
• 31.7. GE Healthcare Bio Sciences AB
• 31.8. Quest Diagnostics Incorporated
• 31.9. Agilent Technologies Inc.
• 31.10. Illumina Inc.
• 31.11. Qiagen Inc.
• 31.12. Myriad Genetic Laboratories Inc.
• 31.13. NeoGenomics Laboratories Inc.
• 31.14. Canon Medical Systems Corporation
• 31.15. Eon Health Inc.

32. Global Lung Cancer Diagnostic And Screening Market Competitive Benchmarking

33. Global Lung Cancer Diagnostic And Screening Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market

35. Lung Cancer Diagnostic And Screening Market Future Outlook and Potential Analysis

• 35.1 Lung Cancer Diagnostic And Screening Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Lung Cancer Diagnostic And Screening Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Lung Cancer Diagnostic And Screening Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer